Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Jake Freeman might be the first meme activist. The 20-year-old New Jersey student, with help from friends and family, burst onto the scene after the Financial Times profiled him and his group's 6.2% Bed, Bath and Beyond (US:BBBY) stake that's earned them $110 million in the company's recent run-up.

Bed, Bath (BBBY) Shareholders Buffeted by Large Meme Player Sales, MindMed (MNMD) Now in Their Sight

Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is a hot topic on Friday as the company's shares continue to rally higher with investors seeing it as a short-squeeze target. But that's not the only reason shares of MNMD are on the move today.

The Hidden Reason MindMed (MNMD) Stock Is Still Climbing

Avaya Holdings

Palisade Bio

Here's what you need to know about buying penny stocks on August 19th The post Hot Penny Stocks to Add to Your Watchlist Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your Watchlist Right Now

Investors appear to think that MindMed could deliver huge gains the way Bed Bath & Beyond has in recent weeks.

Why Mind Medicine (MindMed) Stock Is Crushing It Today

Penny stock Mind Medicine (NASDAQ: MNMD ) stock nearly doubled overnight on rumors of a short squeeze. Shares that opened at 68 cents early on Aug. 17 were trading at $1.16 before the market opened on Aug. 18, after trading as high as $1.40 earlier in the morning.

Is MindMed (MNMD) Stock the Next Big Short Squeeze?

Ensysce Biosciences

VistaGen Therapeutics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 3 Under $0.99 For Your Watch List

Investors trade up the psychedelics-focused biotech's shares after an eventful day.

Why Mind Medicine Stock Crushed the Market on Friday

AppTech Corp

Embark Technology

Canoo

Lexicon Pharmaceuticals

Hot penny stocks to watch or buy for under $5? Here's a list of .penny stocks gaining momentum today The post 5 Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy For Under $5

Opiant Pharmaceuticals

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board.

MindMed Strengthens Board with Appointment of Two New Independent Directors

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Robert Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Elemer Piros - ROTH Capital Partners Patrick Trucchio - H.C. Wainwright Sepehr Manochehry - Eight Capital Operator Good afternoon and welcome to the Mind Medicine Second Quarter 2022 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2022 Results - Earnings Call Transcript

– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022 – – Appoints Drs. Suzanne Bruhn and Roger Crystal as independent members of the Board of Directors – – Strengthened leadership team with the appointment of Schond L.

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

SHERIDAN, Wyo. , Aug. 11, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM") announced that it has sent a letter to the Board of Directors of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed") calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed's at-the-money equity offering.

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

COMPASS Pathways

Cybin

The incredible healing properties of psychedelics are being discovered with every passing day. Their potential is massive and can flip the script for those struggling with mental health disorders.

3 Best Psychedelic Stocks to Buy Now

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares of common shares issued and outstanding1.

MindMed Board of Directors Approves Reverse Share Split

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update

NEW YORK , Aug. 2, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022. Canaccord Genuity 42nd Annual Growth Conference Format: In-person presentation and scheduled one-on-one investor meetingsDate: Wednesday, August 10, 2022 Time: 11:00 a.m.

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Atai Life Sciences BV

Defiance Next Gen Altered Experience ETF

PSYK ETF

Seelos Therapeutics

Advisorshares Psychedelics ETF

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows.

The Growth Potential Of Psychedelics Stocks And ETFs

Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first on InvestorPlace.

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

NEW YORK , June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting"). Election of Directors The five nominees of management were elected as directors at the Meeting.

Mindmed Announces Voting Results for Annual General and Special Meeting

NEW YORK , June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022. Jefferies Global Healthcare Conference Format: In-person presentation and scheduled one-on-one investor meetingsPresentation Date: Friday, June 10, 2022 Time: 12:45 p.m.

MindMed to Participate in the Jefferies Global Healthcare Conference

iQIYI

Nerdy

Penny stocks to buy according to analysts The post Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152%

NEW YORK , May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer.

MindMed Appoints Schond L. Greenway as Chief Financial Officer

- Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal - - Phase 2a trial remains on track to initiate in Q2 2022 - NEW YORK , May 19, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers. The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal.

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

Mind Medicine(NASDAQ:MNMD ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli - Executive President Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Okunewitch - Maxim Elemer Piros - ROTH Capital Sepehr Manochehry - Eight Capital Tania Armstrong-Whitworth - Canaccord Genuity Operator Good morning and welcome to the Mind Medicine First Quarter 2022 Financial Results and Corporate Update Conference Call.

Mind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcript

- Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer - - Cash runway through key clinical readouts in 2023 and into 2024 - - Company to host conference call today at 8:30 AM ET - NEW YORK , May 16, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2022. "The outset of 2022 was marked by significant progress across all aspects of the company that propelled our business forward, as we continued to advance and de-risk our three lead product candidates: MM-120 for the treatment of generalized anxiety disorder, MM-402 for the treatment of core symptoms of autism spectrum disorder, and MM-110 for the management of opioid use disorder," said Robert Barrow, Chief Executive Officer and Director of MindMed.

News for Mind Medicine MindMed Stock (MNMD)